This article is more than 5 years old. Information may no longer be current.

Allergan considers bid for Shire

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan is considering a possible offer for Shire and is evaluating a range of potential strategic actions, the company announced in a press release.

No offer has been made, and there is no certainty an offer will be made, the company said in response to media speculation.

Allergan must announce its intention to make an offer or not make an offer by May 17 under the Takeover Code.

Allergan is considering an offer for Shire.

Source: Shutterstock

The Japanese-based pharmaceutical firm Takeda announced it offered to acquire Shire for a price equivalent to 46.50 pounds per share, comprised of 17.75 pounds in cash and 28.75 pounds in new Takeda shares. However, Shire’s board rejected the proposal.

The two parties are continuing discussions regarding subsequent offers, according to a Takeda press release.